Table 1.
Distribution of subjects and frequency of responders in this study
| Influenza subtype | #Seroneg @ Day 0a, n (%) | Responders (≥4-fold increase)c, n (%) | #Seropos @Day 0b, n (%) | Responders (≥4-fold increase)c, n (%) | #Seroneg @Day 0a, n (%) | Responders (≥4-fold increase)c, n (%) | #Seropos @Day 0b, n (%) | Responders (≥4-fold increase)c, n (%) |
|---|---|---|---|---|---|---|---|---|
| FluBlok | ||||||||
| Year 1 (n = 10) | Year 2 (n = 22) | |||||||
| H1 | 3 (30%) | 3 (100%) | 7 (70%) | 6 (86%) | 4 (18%) | 2 (50%) | 18 (82%) | 13 (72%) |
| H3 | 3 (30%) | 3 (100%) | 7 (70%) | 6 (86%) | 1 (5%) | 1 (100%) | 21 (96%) | 10 (48%) |
| B | 3 (30%) | 1 (33%) | 7 (70%) | 4 (57%) | 7 (32%) | 1 (14.3%) | 15 (68%) | 3 (20%) |
| FluCelvax | ||||||||
| Year 1 (n = 12) | Year 2 (n = 26) | |||||||
| H1 | 4 (33%) | 4 (100%) | 8 (67%) | 4 (50%) | 2 (8%) | 2 (100%) | 24 (92%) | 13 (54%) |
| H3 | 3 (25%) | 2 (67%) | 9 (75%) | 6 (67%) | 2 (8%) | 2 (100%) | 24 (92%) | 15 (63%) |
| B | 3 (25%) | 2 (67%) | 9 (75%) | 2 (22%) | 6 (23%) | 5 (83%) | 20 (77%) | 3 (15%) |
| Fluzone | ||||||||
| Year 1 (n = 9) | Year 2 (n = 22) | |||||||
| H1 | 0 (0%) | 0 (0%) | 9 (100%) | 5 (56%) | 0 (0%) | 0 (0%) | 22 (100%) | 5 (23%) |
| H3 | 6 (67%) | 6 (100%) | 3 (33%) | 3 (100%) | 2 (9%) | 1 (50%) | 20 (91%) | 4 (20%) |
| B | 3 (33%) | 3 (100%) | 6 (67%) | 3 (50%) | 5 (23%) | 1 (20%) | 17 (77%) | 4 (24%) |
aSeronegatives are defined as individuals with pre-vaccination (Day 0) HI titers of <40
bSeropositives are defined as individuals with pre-vaccination (Day 0) HI titers of >40
cResponders are defined as >4-fold increase in post-vaccination (Day 28) titers over pre-vaccination (Day 0) titers